Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. – REGN
12:00pm, Saturday, 18'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:RE
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
11:15am, Saturday, 18'th Jan 2025
LOS ANGELES, CA / ACCESS Newswire / January 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals
SAN DIEGO, Jan. 18, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities betwee
NEW YORK CITY, NY / ACCESS Newswire / January 18, 2025 / WHY: New York, N.Y., January 18, 2025.
NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / WHY: New York, N.Y., January 17, 2025.
Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
05:45pm, Friday, 17'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
SAN DIEGO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceu
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
SAN FRANCISCO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024, wipin
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Friday, 17'th Jan 2025
LOS ANGELES , Jan. 17, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REG
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
LOS ANGELES, CA / ACCESS Newswire / January 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:52am, Friday, 17'th Jan 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
